Cargando…
Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series
Osteogenesis imperfecta (OI) is a connective tissue disorder that is characterized by low bone density leading to recurrent fractures. The efficacy of the anti-resorption drug denosumab for OI with osteoporosis is still largely unknown. We herein describe the clinical outcomes of eight osteoporotic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306860/ https://www.ncbi.nlm.nih.gov/pubmed/30477250 http://dx.doi.org/10.3390/jcm7120479 |
_version_ | 1783382874040303616 |
---|---|
author | Kobayashi, Tsukasa Nakamura, Yukio Suzuki, Takako Yamaguchi, Tomomi Takeda, Ryojun Takagi, Masaki Hasegawa, Tomonobu Kosho, Tomoki Kato, Hiroyuki |
author_facet | Kobayashi, Tsukasa Nakamura, Yukio Suzuki, Takako Yamaguchi, Tomomi Takeda, Ryojun Takagi, Masaki Hasegawa, Tomonobu Kosho, Tomoki Kato, Hiroyuki |
author_sort | Kobayashi, Tsukasa |
collection | PubMed |
description | Osteogenesis imperfecta (OI) is a connective tissue disorder that is characterized by low bone density leading to recurrent fractures. The efficacy of the anti-resorption drug denosumab for OI with osteoporosis is still largely unknown. We herein describe the clinical outcomes of eight osteoporotic cases of OI to examine the effects and safety of denosumab. This retrospective, consecutive case series included eight patients respectively aged 42, 40, 14, 22, 3, 51, 37, and 9 years. We measured the bone mineral density (BMD) of the lumbar 1–4 spine (L-BMD) and bilateral hips (H-BMD), bone-specific alkaline phosphatase, urinary type I collagen amino-terminal telopeptide, and tartrate-resistant acid phosphatase 5b before and during denosumab therapy. Despite multiple pretreatment fractures in the cohort, no fractures or severe side effects, such as hypocalcemia, were observed during the observational period apart from a fracture in a young pediatric girl. Both L-BMD and H-BMD were increased by denosumab in seven of eight cases. Bone turnover markers were inhibited in most cases by denosumab therapy. Denosumab treatment could generally raise BMD without any adverse effects. The agent therefore represents a good therapeutic option for OI with osteoporosis. |
format | Online Article Text |
id | pubmed-6306860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63068602019-01-02 Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series Kobayashi, Tsukasa Nakamura, Yukio Suzuki, Takako Yamaguchi, Tomomi Takeda, Ryojun Takagi, Masaki Hasegawa, Tomonobu Kosho, Tomoki Kato, Hiroyuki J Clin Med Article Osteogenesis imperfecta (OI) is a connective tissue disorder that is characterized by low bone density leading to recurrent fractures. The efficacy of the anti-resorption drug denosumab for OI with osteoporosis is still largely unknown. We herein describe the clinical outcomes of eight osteoporotic cases of OI to examine the effects and safety of denosumab. This retrospective, consecutive case series included eight patients respectively aged 42, 40, 14, 22, 3, 51, 37, and 9 years. We measured the bone mineral density (BMD) of the lumbar 1–4 spine (L-BMD) and bilateral hips (H-BMD), bone-specific alkaline phosphatase, urinary type I collagen amino-terminal telopeptide, and tartrate-resistant acid phosphatase 5b before and during denosumab therapy. Despite multiple pretreatment fractures in the cohort, no fractures or severe side effects, such as hypocalcemia, were observed during the observational period apart from a fracture in a young pediatric girl. Both L-BMD and H-BMD were increased by denosumab in seven of eight cases. Bone turnover markers were inhibited in most cases by denosumab therapy. Denosumab treatment could generally raise BMD without any adverse effects. The agent therefore represents a good therapeutic option for OI with osteoporosis. MDPI 2018-11-24 /pmc/articles/PMC6306860/ /pubmed/30477250 http://dx.doi.org/10.3390/jcm7120479 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kobayashi, Tsukasa Nakamura, Yukio Suzuki, Takako Yamaguchi, Tomomi Takeda, Ryojun Takagi, Masaki Hasegawa, Tomonobu Kosho, Tomoki Kato, Hiroyuki Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title | Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title_full | Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title_fullStr | Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title_full_unstemmed | Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title_short | Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series |
title_sort | efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis—case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306860/ https://www.ncbi.nlm.nih.gov/pubmed/30477250 http://dx.doi.org/10.3390/jcm7120479 |
work_keys_str_mv | AT kobayashitsukasa efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT nakamurayukio efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT suzukitakako efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT yamaguchitomomi efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT takedaryojun efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT takagimasaki efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT hasegawatomonobu efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT koshotomoki efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries AT katohiroyuki efficacyandsafetyofdenosumabtherapyforosteogenesisimperfectapatientswithosteoporosiscaseseries |